Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report by unknown
JOURNAL OF MEDICAL
CASE REPORTS
Jayaweera et al. Journal of Medical Case Reports 2014, 8:442
http://www.jmedicalcasereports.com/content/8/1/442CASE REPORT Open AccessCyclophosphamide-induced posterior reversible
encephalopathy syndrome (PRES): a case report
Jayamalee L Jayaweera1, Milinda R Withana1,4*, Chamila KP Dalpatadu1, Chathurika D Beligaswatta1,
Thamara Rajapakse2, Saroj Jayasinghe3 and Thashi Chang3Abstract
Introduction: Posterior reversible encephalopathy syndrome is a clinicoradiologic entity characterized by headache,
seizures, decreased vision, impaired consciousness and white matter oedema in bilateral occipitoparietal regions.
Hypertensive encephalopathy, eclampsia, immunosuppressive/cytotoxic drugs, organ transplantation, renal disease,
autoimmune diseases and vasculitides are reported risk factors of posterior reversible encephalopathy syndrome.
Reports of cyclophosphamide-induced posterior reversible encephalopathy syndrome are rare and occurred in a
background of renal failure, fluid overload or active connective tissue disease.
Case presentation: We report a case of posterior reversible encephalopathy syndrome developing as a direct
consequence of intravenous cyclophosphamide therapy in a 33-year-old normotensive Sri Lankan woman with
lupus nephritis but quiescent disease activity and normal renal function.
Conclusions: This case report highlights the need for awareness and early recognition of this rare but serious
adverse effect of cyclophosphamide that occurred in the absence of other known risk factors of posterior reversible
encephalopathy syndrome and that early appropriate intervention leads to a good outcome.
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Posterior reversible encephalopathy syndrome (PRES)
is a clinicoradiologic entity characterized by headache,
changes of sensorium, seizures, visual disturbances and
vasogenic oedema on neuroimaging [1]. A possible link
between autoimmune disorders and PRES has been re-
cently hypothesized [2,3]. A susceptibility of the ce-
rebrovascular system to insults such as inflammation,
hypertension, nephritis, and cytotoxic drugs has been
recognized [3,4]. Cyclophosphamide is an alkylating
agent that is widely used in the treatment of selected
malignant processes and autoimmune diseases. How-
ever, reports of cyclophosphamide-induced PRES are
rare [5,6]. We report the case of a 33-year-old normo-
tensive patient with lupus nephritis who developed PRES
following intravenous cyclophosphamide therapy.* Correspondence: milishan2003@gmail.com
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A 33-year-old Sri Lankan woman presented with inter-
mittent inflammatory polyarthritis and low-grade fever
of 2 months. She had a childhood history of nephritic
syndrome but never had seizures, psychiatric illness or
hypertension. On examination, she was pale, had general-
ized oedema and active non-deforming arthritis involving
small and large joints. Urine analysis showed albuminuria,
2 to 3 red blood cells (RBC) per high-power field and RBC
casts. Autoimmune screening was positive for antinuclear
antibodies (titre >1:160), anti-double-stranded DNA, and
a low complement C3 level of 39.3mg/dL (normal range:
55 to 120) and a C4 level of 10.1mg/dL (normal range: 20
to 50). A renal biopsy showed World Health Organization
class IV lupus nephritis. Based on a diagnosis of active
lupus nephritis, she was treated with 1000mg (15mg/kg/
day) of intravenous methylprednisolone for 3 days and
500mg of intravenous cyclophosphamide. She was dis-
charged from hospital on a maintenance dose of oral
prednisolone of 1mg/kg/day.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Magnetic resonance fluid-attenuated inversion
recovery image demonstrating symmetrical, hyper intense,
white matter lesions in bilateral posterior occipital regions.
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dose of intravenous cyclophosphamide in keeping with
the treatment guidelines of the Euro-Lupus Nephritis
Trial [7]. On admission, she was clinically well with nor-
mal blood counts and inflammatory markers, and a blood
pressure of 115/70mmHg. Four hours after completion of
the cyclophosphamide infusion she developed generalized
tonic–clonic seizures (GTCS). In the next 6 hours, she de-
veloped eight GTCS and her level of consciousness deteri-
orated to a Glasgow Coma Scale (GCS) score of 7/15. She
was noted to have a downward gaze with equally reacting
pupils and bilaterally extensor plantar reflexes. She was
afebrile and did not have neck stiffness. Her blood pres-
sure remained within normal limits. Her haematological
and biochemical parameters were within normal limits
(haemoglobin 11.8g/dL; white cell count of 9400/ mm3;
platelet count 236,000/mm3; normal blood picture; blood
glucose 101mg/dL; serum sodium 141mmol/L; potassium
4.3mmol/L; serum creatinine 99μmol/L; serum ionized
calcium 2.2mmol/L; serum magnesium 1.1mmol/L). Her
blood and urine cultures were sterile. Her urine analy-
sis was normal except for proteinuria of 30mg/dL. Her
erythrocyte sedimentation rate was 18mm/hour, C-reactive
protein was 3.3mg/dL, and her complement levels (both
C3 and C4) remained within normal limits.
She was electively ventilated. Seizure control was ob-
tained with intravenous midazolam and phenytoin with
concurrent nasogastrically delivered high-dose sodium
valproate and topiramate.
Magnetic resonance imaging of her brain showed sym-
metrical high-intensity signals confined to the white mat-
ter in both occipital regions (Figure 1) with no diffusion
restriction (Figure 2) or contrast enhancement compatible
with PRES. Magnetic resonance angio- and venograms
were normal.
Her level of consciousness improved over the ensuing
24 hours and she was weaned off the ventilator after 48
hours. Her GCS recovered to 15/15 and she remained
seizure-free on oral antiepileptic drugs.Figure 2 Diffusion-weighted axial magnetic resonance imaging
brain image showing no abnormalities.Discussion
Our case report highlights a rare but serious compli-
cation of cyclophosphamide pulse therapy in a patient
with recently diagnosed class IV lupus nephritis. Although
PRES has been reported in association with systemic
lupus erythematosus (SLE) and renal disease [5], given
that she had quiescent disease activity (Systemic Lupus
Erythematosus Disease Activity Index of 2/101) at the
time of developing PRES and that it was temporally re-
lated to the administration of the drug, cyclophospha-
mide was considered the most likely aetiological factor.
PRES is generally considered to have a benign outcome
but grave consequences have been reported in somecase series [8] and it is likely to cause irreversible damage
if the inciting agent is not removed early.
The underlying pathophysiology of PRES remains elu-
sive but is thought to be a loss of cerebral vascular
autoregulation, probably with endothelial dysfunction,
in the setting of an acute rise in systemic blood pres-
sure [1]. Cerebral white matter is composed of loosely
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ceptible to vasogenic oedema. The relative deficiency of
vasoconstrictor-adrenergic innervation of the vertebro-
basilar system compared to the vessels of the carotid
system has been hypothesized to explain the posterior
preponderance of PRES. However, PRES lesions have been
reported to occur in the anterior circulation territory as
well as in normotensive patients [8,9]. In these cases,
breakdown of the blood–brain barrier due to endothe-
lial dysfunction caused by certain drugs or underlying
conditions such as fluid overload or renal insufficiency
have been postulated [3]. Abnormal endothelial activa-
tion, dysfunction and leukocyte tracking have recently
been reported to cause cerebral and systemic hypoper-
fusion, which may be causative factors for PRES in SLE
[6,10]. In general, patients with SLE who developed
PRES had a high disease activity index at the time of
its occurrence [2,5,11].
Cyclophosphamide use has been reported in several
cases of PRES, but mostly in combination with other
cytotoxic agents for treatment of haematological malig-
nancies [2,12]. Furthermore, PRES attributed to cyclo-
phosphamide is confounded by the presence of fluid
overload, hypertension, and/or renal failure, all of which
could contribute to endothelial dysfunction [2,6]. In con-
trast, our patient did not have any such inciting factors
apart from cyclophosphamide therapy, thus making it
the most likely causative factor. Early recognition and
appropriate therapy ensured a rapid and complete recov-
ery in our patient. The risk of recurrence of PRES with
reuse of cyclophosphamide remains unresolved [5,12]. If
the indication permits then an alternative cytotoxic agent
may be used. However, close monitoring for recurrence
would be necessary.Conclusions
Our case report illustrates the occurrence of PRES fol-
lowing administration of cyclophosphamide in a patient
who had no other known risk factors for PRES. It high-
lights the need for a high index of suspicion and a good
outcome related to early recognition and appropriate
intervention.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
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